Ultragenyx Pharmaceutical (RARE) Goodwill (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Goodwill for 10 consecutive years, with $44.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Goodwill fell 0.91% year-over-year to $44.0 million; the TTM figure through Mar 2026 stood at $44.0 million (down 0.91% YoY), while the FY2025 annual figure was $44.0 million, changed 0.0% from the prior year.
• Goodwill steadied at $44.0 million in Q1 2026 per RARE's latest filing, from $44.0 million in the prior quarter.
• Across five years, Goodwill topped out at $44.4 million in Q1 2022 and bottomed at $44.0 million in Q4 2024.
• Historically, Goodwill has averaged $44.3 million across 5 years, with a median of $44.4 million in 2022.
• Annual changes were most pronounced in 2022 — Goodwill changed 0.0% — and 2024, when it declined 0.91%.
• Ultragenyx Pharmaceutical's Goodwill stood at $44.4 million in 2022, then changed by 0.0% to $44.4 million in 2023, then fell by 0.91% to $44.0 million in 2024, then changed by 0.0% to $44.0 million in 2025, then changed by 0.0% to $44.0 million in 2026.
• Business Quant data shows RARE's Goodwill at $44.0 million in Q1 2026, $44.0 million in Q4 2025, and $44.4 million in Q3 2025.